Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has announced a three-year supply contract with Samsung Electronics (Samsung Healthcare). This collaboration aims to revolutionize lung screening by integrating Lunit’s AI technology into Samsung’s premium X-ray devices, enhancing accuracy and speed.
Under the terms of the contract, Lunit will supply Samsung Electronics with two AI-powered chest screening solutions: Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage. Initially, the collaboration will focus on the markets in the US, Canada, and Europe, with future plans to expand to the Middle East, South America, and Southeast Asia.
The integration of Lunit’s AI solutions into Samsung’s X-ray devices will be particularly beneficial in high-stakes medical settings such as Intensive Care Units (ICUs) and Emergency Rooms (ERs). X-ray devices enhanced with Lunit INSIGHT CXR Triage will prioritize the detection of critical findings, enabling a timely review process for intervention.
Brandon Suh, CEO of Lunit, expressed excitement about the partnership, stating that it will lead to faster and more accurate chest screenings, ultimately improving patient outcomes. Lunit INSIGHT CXR is capable of detecting common lung abnormalities, including lung cancer, pneumonia, and pneumothorax. Lunit INSIGHT CXR Triage, an FDA-cleared AI solution, identifies pre-specified critical findings on frontal chest X-ray images, further facilitating the review process.
Founded in 2013, Lunit is a medical AI company focused on using deep learning-based algorithms to conquer cancer. Their flagship product, Lunit INSIGHT suite, is currently used in over 3,000 hospitals and medical institutions across 40+ countries, contributing to accurate cancer diagnosis and optimal treatment.
This collaboration between Lunit and Samsung Electronics has the potential to advance chest X-ray practices globally, offering improved accuracy and speed in lung screening. By integrating AI technology into Samsung’s premium X-ray devices, healthcare professionals can expect enhanced capabilities for detecting lung abnormalities, leading to timely interventions and better patient outcomes.
About Lunit:
Lunit is a medical AI company dedicated to harnessing AI to ensure accurate cancer diagnosis and optimal treatment for each patient. With its AI-powered medical image analytics and AI biomarkers, Lunit is committed to conquering cancer. The company’s findings are published in major peer-reviewed journals and presented at global conferences, solidifying its position as a leading player in the field. Headquartered in Seoul, South Korea, Lunit has a global presence with offices and representatives worldwide.
In conclusion, the partnership between Lunit and Samsung Electronics seeks to revolutionize lung screening through the integration of AI technology into premium X-ray devices. By enhancing accuracy and speed, this collaboration aims to provide faster and more accurate chest screenings, particularly in high-stakes medical settings. Lunit’s AI-powered solutions, combined with Samsung’s X-ray devices, are set to improve the detection and treatment of lung abnormalities, ultimately leading to better patient outcomes globally.
